Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.09.19
Views: 1099

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

Prof Simon Harrison talks to ecancer at the International Myeloma Workshop 2019 about the BELLINI study.

Prof Harrison begins by outlining the study design and results of the BELLINI study. 

He explains how toxicities were an issue with respect to the overall survival, and suggests why these toxicities might be occurring.

Prof Harrison explores the idea of other possibilities, but reminds us that we should not ignore venetoclax altogether.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content. 

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation